← Back to Search

Chemotherapy

AZD2811 for Small Cell Lung Cancer (TAZMAN Trial)

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of two drugs, AZD2811 and Durvalumab, to maintain cancer control in adults with advanced small-cell lung cancer who responded well to earlier treatment. AZD2811 stops cancer cell growth, and Durvalumab helps the immune system fight the cancer. Durvalumab has shown survival benefits in various cancers, including non-small cell lung cancer.

Eligible Conditions
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Assess safety and tolerability profile in terms safety assessments, adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5.0, and dose modifications
EORTC 13: Lung cancer specific quality of life based on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire - Lung Cancer (QLQ-LC13) v1.0.
EORTC 30: Health related quality of life based on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire - Cancer (QLQ-C30) v3.0.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AZD2811 + DurvalumabExperimental Treatment5 Interventions
Induction: Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin \& Etoposide) Maintenance: AZD2811 + Durvalumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6120
Durvalumab
2017
Completed Phase 2
~3780
AZD2811
2015
Completed Phase 1
~80
Cisplatin
2013
Completed Phase 3
~3120
Etoposide
2010
Completed Phase 3
~2960

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,379 Previous Clinical Trials
288,740,259 Total Patients Enrolled
~7 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top